Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Nom du journal : BMC Cancer

Année : 2018

Volume : 18

Page de départ : 963

Auteurs: Gonçalves A, Ryckewaert T, Lebellec L, Mir O, Tresch-Bruneel E, Bertucci F, Bompas E, Italiano A, Le Deley MC, Penel N, Blay JY, Le Cesne A, Ray-Coquard I, Toiron Y, Camoin L,